BioWorld

March 20, 2009

Cortex Slashing Half its Staff in Latest Round of Belt-Tightening

Cortex Pharmaceuticals Inc. is cutting about half its staff, slashing executive salaries and putting some research projects on the back burner, all in an effort to stay afloat in the troubled economy. (BioWorld Today) Read More

Genome Scan Studies Hold Promise for Cancer Research

Double-Duty Herceptin Variant Challenges Antibody Dogma

Arthritis: How Will it Impact the Biotech and Med-Tech Markets?

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...